EyePoint Pharmaceuticals (United Kingdom).
company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery
- Reports this week
- 1
- Active events
- 2
- Connections
- 28
What's happening
Active this week
Earlier this month
One to three months ago
-
EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.Some support2 reports
-
EyePoint Pharmaceuticals reported that Wet AMD is the leading cause of vision loss in the US.Some support2 reports1 development inside
-
EyePoint Pharmaceuticals developed Duravyu for wet AMD treatment.Some support1 report
-
MarketBeat is discussing EyePoint Pharmaceuticals, a company based in the United Kingdom, as a high-risk investment target.Some support1 report
-
Analyst firm issues research notes on EyePoint Pharmaceuticals, which is listed on the Nasdaq stock exchange.Some support3 reports
-
Citigroup raised its price objective and issued a buy rating for EyePoint Pharmaceuticals, which trades on Nasdaq.Some support3 reports
Gone quiet
No new reports in 90+ days-
EyePoint Pharmaceuticals granted stock options under a NASDAQ listing rule on August 19, 2025.Some support3 reports1 development inside
-
Jay S. Duker leads EyePoint's execution across business aspects.Some support3 reports
-
Rhythm and EyePoint Pharmaceuticals are companies operating within the same industry.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around EyePoint Pharmaceuticals (United Kingdom) this week
News at the entities that move EyePoint Pharmaceuticals (United Kingdom) most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves EyePoint Pharmaceuticals (United Kingdom)
-
Citigroup Mentioned togetherCitigroup provided analyst ratings and targets for Autodesk stock, which trades on Nasdaq.Moves EyePoint Pharmaceuticals (United Kingdom)
-
Jefferies Financial Group Mentioned togetherApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves EyePoint Pharmaceuticals (United Kingdom)
-
MarketBeat Mentioned togetherMarketBeat aggregates data on IDT Corporation stock performance.Moves EyePoint Pharmaceuticals (United Kingdom)
-
TD Cowen Mentioned togetherAnalyst downgraded Ag Growth International Inc. due to debt management risks.Moves EyePoint Pharmaceuticals (United Kingdom)
-
Royal Bank of Canada Mentioned togetherRoyal Bank of Canada raised its holdings in the Dimensional US Sustainability Core 1 ETF on June 19, 2026.Moves EyePoint Pharmaceuticals (United Kingdom)
Connections
The 11 strongest of 28, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Jay S. Duker Structural
Jay S. Duker holds the executive role of President and CEO at EyePoint Pharmaceuticals.
-
Nasdaq Structural
EyePoint Pharmaceuticals lists and trades its shares on the Nasdaq stock exchange.
-
FDA Structural
EyePoint Pharmaceuticals relies on the FDA for regulatory approval of its products.
-
Citigroup Mentioned together
Citigroup provides financial analysis, including buy ratings and price objectives, for EyePoint Pharmaceuticals.
-
MarketBeat Mentioned together
MarketBeat tracks and reports consensus rating data for EyePoint Pharmaceuticals as an investment target.
-
Jefferies Financial Group Mentioned together
Jefferies Financial Group provided a buy rating upgrade for EyePoint Pharmaceuticals.
-
company Mentioned together
EyePoint Pharmaceuticals is mentioned in the context of financial investigation within the broader corporate sector.
-
Y. Chen Mentioned together
Analyst research notes connect the two entities within market coverage.
Show all 11 connections
-
Cantor Fitzgerald Mentioned together
Both companies are covered by analyst reports providing ratings and price targets.
-
TD Cowen Mentioned together
TD Cowen provided financial analysis, slashing the target price for EyePoint Pharmaceuticals.
-
Royal Bank of Canada Mentioned together
RBC has influenced market perception of EyePoint by adjusting its target price and rating.
History
Events by the month they beganSeptember 2026
2 eventsAugust 2026
3 eventsJune 2026
7 events- Trump's pledge to unleash American oil and gas benefits certain stocks, impacting EyePoint Pharmaceuticals.
- EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.
- EyePoint Pharmaceuticals reported that Wet AMD is the leading cause of vision loss in the US.
- Citigroup raised its price objective and issued a buy rating for EyePoint Pharmaceuticals, which trades on Nasdaq.
- EyePoint Pharmaceuticals granted stock options under a NASDAQ listing rule on August 19, 2025.
- Jay S. Duker leads EyePoint's execution across business aspects.
- Rhythm and EyePoint Pharmaceuticals are companies operating within the same industry.